SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 109, Issue 1, 2015, Pages 57-63

  He, Rui ^a   Zhang, Dandan ^a   Lu, Wei ^a   Zheng, Taishan ^a   Wan, Lili ^a   Liu, Fang ^a   Jia, Weiping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

MATE 1; Metformin; Rs2289669 G>A variants; SLC47A1; Type 2 diabetes

Indexed keywords

CYSTATIN C; HEMOGLOBIN A1C; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ANTIDIABETIC AGENT; MATE1 PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BRAIN HEMORRHAGE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; SMOKING; TIME TO MAXIMUM PLASMA CONCENTRATION; WAIST CIRCUMFERENCE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; GENETICS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADMINISTRATION, ORAL; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84930822213     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.05.003     Document Type: Article

References (28)

1. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
2. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med 2002, 137:25-33.
3. Hermann L.S., Schersten B., Bitzen P.O., Kjellstrom T., Lindgarde F., Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994, 17:1100-1109.
4. Cook M.N., Girman C.J., Stein P.P., Alexander C.M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care. Diabetic Med 2007, 24:350-358. (a journal of the British Diabetic Association).
5. Cusi K., Consoli A., DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996, 81:4059-4067.
6. Chen Y., Li S., Brown C., Cheatham S., Castro R.A., Leabman M.K., et al. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009, 19:497-504.
7. Song I.S., Shin H.J., Shim E.J., Jung I.S., Kim W.Y., Shon J.H., et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008, 84:559-562.
8. Stocker S.L., Morrissey K.M., Yee S.W., Castro R.A., Xu L., Dahlin A., et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 2013, 93:186-194.
9. Otsuka M., Matsumoto T., Morimoto R., Arioka S., Omote H., Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005, 102:17923-17928.
10. Becker M.L., Visser L.E., van Schaik R.H., Hofman A., Uitterlinden A.G., Stricker B.H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009, 58:745-749.
11. Tkac I., Klimcakova L., Javorsky M., Fabianova M., Schroner Z., Hermanova H., et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes, Obes Metab 2013, 15:189-191.
12. American Diabetes Association Standards of medical care in diabetes-2012. Diabetes Care 2012, 35(Suppl 1):S11-S63.
13. Shu Y., Brown C., Castro R.A., Shi R.J., Lin E.T., Owen R.P., et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Therap 2008, 83:273-280.
14. Toyama K., Yonezawa A., Tsuda M., Masuda S., Yano I., Terada T., et al. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet Genomics 2010, 20:135-138.
15. Christensen M.M., Brasch-Andersen C., Green H., Nielsen F., Damkier P., Beck-Nielsen H., et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011, 21:837-850.
16. Shu Y., Sheardown S.A., Brown C., Owen R.P., Zhang S., Castro R.A., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117:1422-1431.
17. Kimura N., Okuda M., Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharmaceut Res 2005, 22:255-259.
18. Wang D.S., Jonker J.W., Kato Y., Kusuhara H., Schinkel A.H., Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002, 302:510-515.
19. Kimura N., Masuda S., Tanihara Y., Ueo H., Okuda M., Katsura T., et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005, 20:379-386.
20. Motohashi H., Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J 2013, 15:581-588.
21. Omote H., Hiasa M., Matsumoto T., Otsuka M., Moriyama Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 2006, 27:587-593.
22. Konig J., Zolk O., Singer K., Hoffmann C., Fromm M.F. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2011, 163:546-555.
23. Ha Choi J., Wah Yee S., Kim M.J., Nguyen L., Ho Lee J., Kang J.O., et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 2009, 19:770-780.
24. Chen Y., Teranishi K., Li S., Yee S.W., Hesselson S., Stryke D., et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009, 9:127-136.
25. Graham G.G., Punt J., Arora M., Day R.O., Doogue M.P., Duong J.K., et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011, 50:81-98.
26. Tsuda M., Terada T., Mizuno T., Katsura T., Shimakura J., Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 2009, 75:1280-1286.
27. Yonezawa A., Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol 2011, 164:1817-1825.
28. +/organic cation antiporter MATE1. Am J Physiol Renal Physiol 2007, 293:F1564-F1570.